New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Open Access
- 29 August 2022
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1200
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerative disorders displaying substantial overlay, although there are substantial differences at the molecular level. Currently, there is no effective treatment for these diseases. The transcription factor NRF2 has been postulated as a promising therapeutic target as it is capable of modulating key pathogenic events affecting cellular homeostasis. However, there is little experimental evidence on the status of this pathway in both ALS and FTD. Therefore, in this work, we wanted to carry out an exhaustive analysis of this signaling pathway in both transgenic mouse models (ALS and FTD) and human samples from patients with sporadic ALS (sALS) versus controls. In samples from patients with sALS and in the transgenic model with overexpression of TDP-43A315T, we observed a significant increase in the NRF2/ARE pathway in the motor cortex and the spinal cord, indicating that NRF2 antioxidant signaling was being induced, but it was not enough to reach cellular homeostasis. On the other hand, in the transgenic FTD model with overexpression of the TDP-43WT protein in forebrain neurons, a significantly decreased expression of NQO1 in the prefrontal cortex was seen, which cannot be attributed to alterations in the NRF2 pathway. Our results show that NRF2 signature is differently affected for ALS and FTD.Keywords
Funding Information
- Comunidad de Madrid (B2017/BMD-3813)
- MINECO (PID2019-105600RB-I00)
- ISCiii CIBERNED (CB18/05/00040, CB06/05/0089)
- Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica (2019/00325/001)
This publication has 57 references indexed in Scilit:
- Absence of Nrf2 or Its Selective Overexpression in Neurons and Muscle Does Not Affect Survival in ALS-Linked Mutant hSOD1 Mouse ModelsPLOS ONE, 2013
- The Predicted Molecular Weight of Nrf2: It Is What It Is NotAntioxidants & Redox Signaling, 2013
- TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathiesTrends in Molecular Medicine, 2011
- Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-UJournal of Experimental Medicine, 2010
- TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degenerationProceedings of the National Academy of Sciences, 2009
- Nrf2 Activation in Astrocytes Protects against Neurodegeneration in Mouse Models of Familial Amyotrophic Lateral SclerosisJournal of Neuroscience, 2008
- The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementiaCurrent Opinion in Neurology, 2008
- ALS and FTLD: two faces of TDP‐43 proteinopathyEuropean Journal of Neurology, 2008
- TDP‐43 A315T mutation in familial motor neuron diseaseAnnals of Neurology, 2008
- Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: Protective role of S-allylcysteineFree Radical Research, 2008